Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.

about

The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.Waldenstrom's Macroglobulinemia: An Update.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q46375923-021BF448-D902-4F8A-B63C-DA64A5887E18 Q47736653-3E35A863-0B19-40C1-934E-AE9B9F6AB62B Q55283747-D5A43368-D91B-45C5-B20B-1B3000EC630A

P2860

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.

Item

http://www.wikidata.org/entity/Q38635212

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dexamethasone, rituximab and c ...... Waldenstrom macroglobulinemia.

@en

type

Item

label

Dexamethasone, rituximab and c ...... Waldenstrom macroglobulinemia.

@en

prefLabel

Dexamethasone, rituximab and c ...... Waldenstrom macroglobulinemia.

@en

P1476

Dexamethasone, rituximab and c ...... Waldenstrom macroglobulinemia.

@en

P2093

Amanda Shreders

http://www.w3.org/2001/XMLSchema#string

Craig B Reeder

http://www.w3.org/2001/XMLSchema#string

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

Jithma P Abeykoon

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Jonas Paludo

http://www.w3.org/2001/XMLSchema#string

Nelson Leung

http://www.w3.org/2001/XMLSchema#string

Prashant Kapoor

http://www.w3.org/2001/XMLSchema#string

Rahma Warsame

http://www.w3.org/2001/XMLSchema#string

Rebecca L King

http://www.w3.org/2001/XMLSchema#string

P2860

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

P31

scholarly article

P356

10.1111/BJH.14826

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

P577

2017-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28786474

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.

about

P2860

P2860

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921